Mitapivat-Pyrukynd price inquiry and market trends

Mitapivat-Pyrukynd is a drug used to treat hemolytic anemia caused by pyruvate kinase (PK) deficiency. It is not currently on the Chinese market and is not included in medical insurance. However, mitava is approved and available in other parts of the world, particularly in the United States and Europe.

In overseas markets, the original drug of Metapival is relatively expensive. Taking the United States as an example, the standard specification of Metapival is50mg*56 tablets, and each box sells for about more than 25,000 US dollars. This price places a high financial burden on patients when using the drug, especially if there is no medical insurance reimbursement. For patients without insurance coverage, long-term use of metapival may result in greater treatment costs.

Although the price of metapival is higher, its market prospect is still promising because it provides a new treatment option for patients suffering fromPK deficiency. PK deficiency is a rare genetic disease in which patients suffer from rupture of red blood cells due to pyruvate kinase deficiency. Metapival relieves patients' symptoms and reduces anemia, fatigue and other related problems by enhancing the survival of red blood cells.

Globally, as more countries and regions gradually approve the marketing of mitava, drug prices may change due to market competition and generic drugs. At the same time, since Metapival has not yet been launched in China, patients who need to use the drug may need to purchase it through overseas drug purchase channels, which further increases the cost burden of the drug.

Overall, the high price of metapival limits its popularity among some financially disadvantaged patients, but over time, more insurance companies may consider including it in reimbursement, or more generic options may appear on the market, providing patients with more economical treatment pathways.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd